George Simon and Gerold Bepler were at H. Lee Moffitt Cancer Center and Research Institute when this work was performed.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis
Article first published online: 25 OCT 2011
DOI: 10.1002/cncr.26522
Copyright © 2011 American Cancer Society
Additional Information
How to Cite
Simon, G. R., Schell, M. J., Begum, M., Kim, J., Chiappori, A., Haura, E., Antonia, S. and Bepler, G. (2012), Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer, 118: 2525–2531. doi: 10.1002/cncr.26522
- †
George Simon and Gerold Bepler were at H. Lee Moffitt Cancer Center and Research Institute when this work was performed.
- ‡
George R. Simon generated the study concept and contributed to data tabulation, statistical analysis, and patient accrual; he is a guarantor of the article and takes responsibility for the integrity of the work as a whole, from inception to publication.
- §
Fax: (843) 792-0644
- ¶
Michael J. Schell contributed to statistical analysis of the data. Mubeena Begum contributed to data compilation and analysis.
- ‖
Jongphil Kim contributed to statistical analysis of the data.
- ††
Alberto Chiappori contributed to the accrual of patients and conceptualization of studies in the standard-of-care arms.
- ‡‡
Eric Haura contributed to the accrual of patients and conceptualization of studies in the standard-of-care arms.
- §§
Scott Antonia contributed to the accrual of patients and conceptualization of studies in the standard-of-care arms.
- ¶¶
Gerold Bepler conceptualized the studies and contributed to the analysis of molecular determinants.
Publication History
- Issue published online: 20 APR 2012
- Article first published online: 25 OCT 2011
- Manuscript Accepted: 4 AUG 2011
- Manuscript Revised: 22 JUL 2011
- Manuscript Received: 23 MAY 2011
REFERENCES
- 1, , , . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
- 2, , , et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
- 3, , , et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
- 4, , , et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010; 21: 540-547.
- 5, , , et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
- 6, , , et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
- 7, , . Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007; 39: 1318-1328.
- 8, , , et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006; 24: 4731-4737.
- 9, , , et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007; 25: 2741-2746.
- 10, , , et al. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology. 2005; 68: 382-390.
- 11, , , et al. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008; 112: 2021-2029.
- 12, , , et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008; 14: 1464-1469.
- 13, , , , . ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005; 127: 978-983.
- 14, , . Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw. 2010; 8: 822-832.
- 15, , , et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007; 25: 2747-2754.
- 16, , , et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004; 22: 1878-1885.
- 17, , , et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-991.